Clinical Trial Update: Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Everolimus (RAD001) in combination with Gemcitabine for advanced or metastatic pancreatic adenocarcinoma has been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Everolimus (everolimus)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced or Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED